Synthesis	synthesis	O	O	O	O
of	of	O	O	O	O
N-pyrimidinyl-2-phenoxyacetamides	n-pyrimidinyl-2-phenoxyacetamides	O	O	O	O
as	as	O	O	O	O
adenosine	adenosine	CHEMICALS	O	OTHERS	I
A2A	a2a	O	O	O	O
receptor	receptor	O	O	O	O
antagonists	antagonists	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
series	series	O	O	O	O
of	of	O	O	O	O
N-pyrimidinyl-2-phenoxyacetamide	n-pyrimidinyl-2-phenoxyacetamide	O	O	O	O
adenosine	adenosine	CHEMICALS	O	OTHERS	I
A(2A	a(2a	O	O	O	O
)	)	O	O	O	O
antagonists	antagonists	O	O	O	O
is	is	O	O	O	O
described	described	O	O	O	O
.	.	O	O	O	O

SAR	sar	O	O	O	O
studies	studies	O	O	O	O
led	led	O	O	O	O
to	to	O	O	O	O
compound	compound	O	O	O	O
14	14	O	O	O	O
with	with	O	O	O	O
excellent	excellent	O	O	O	O
potency	potency	O	O	O	O
(	(	O	O	O	O
K(i	k(i	O	O	O	O
)	)	O	O	O	O
=	=	O	O	O	O
0.4	0.4	O	O	O	O
nM	nm	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
selectivity	selectivity	O	O	O	O
(	(	O	O	O	O
A(1)/A(2A	a(1)/a(2a	O	O	O	O
)	)	O	O	O	O
>	>	O	O	O	O
100	100	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
efficacy	efficacy	O	O	O	O
(	(	O	O	O	O
MED	med	O	O	O	O
10	10	O	O	O	O
mg/kg	mg/kg	O	O	O	O
p.o	p.o	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
rat	rat	O	O	O	O
haloperidol-induced	haloperidol-induced	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
model	model	O	O	O	O
for	for	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

